

Edgar Filing: GENOMED INC - Form 8-K/A

GENOMED INC
Form 8-K/A
August 18, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

May 3, 2005

Date of Report (Date of earliest event reported)

GENOMED, INC.

(Exact name of registrant as specified in its charter)

Florida	000-49720	43-1916702
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9666 OLIVE BOULEVARD, SUITE 300, ST. LOUIS, MISSOURI 63131

(Address of principal executive offices) (Zip Code)

(314) 983-9933

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 4.01 Changes in Registrant's Certifying Accountant

(a)(1) On May 3, 2005, GenoMed, Inc. ("the Registrant") changed accountants from

Edgar Filing: GENOMED INC - Form 8-K/A

Rubin, Brown, Gornstein & Co., LLP ("Rubin Brown") to Stark Winter Schenkein & Co., LLP ("Stark Winter").

(i) On May 3, 2005, the Registrant decided to dismiss Rubin Brown as its independent accountants after Rubin Brown declined to stand for re-election as the Registrant's independent accountants.

(ii) Rubin Brown's report on the financial statements for the year ended December 31, 2004, as contained in Form 10-KSB, which was filed on April 4, 2005, was not subject to an adverse or qualified opinion or a disclaimer of opinion and was not modified as to uncertainty, audit scope or accounting principles, except that Rubin Brown's report on the financial statements as of and for the year ended December 31, 2004 contained explanatory language that substantial doubt existed about the Registrant's ability to continue as a going concern due to the Registrant's recurring losses from operations at December 31, 2004.

(iii) The decision to change accountants was approved by the Registrant's Board of Directors; and

(iv) (A) During the period from our engagement of Rubin Brown on July 19, 2004 to the date we dismissed Rubin Brown on May 3, 2005, there were no disagreements with Rubin Brown related to accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements if not resolved to the satisfaction of Rubin Brown, would have caused Rubin Brown to make reference to the subject matter of the disagreement in connection with its report.

(B) Not applicable

(C) Not applicable

(D) Not applicable

(E) Not applicable

(2) On May 3, 2005, the Registrant engaged Stark Winter as its independent accountants.

(i) The Registrant did not consult with Stark Winter, its new independent accountants, regarding any matter prior to its engagement; and

(ii) Not applicable

(3) The Registrant has provided to Rubin Brown, its former accountant, a copy of the disclosures contained in this Item 4.01 and the Registrant has requested a letter from Rubin Brown addressed to the Commission, confirming certain statements made by the Registrant in this Item 4.01. A copy of this letter is attached hereto.

(b) Not applicable

Item 9.01 Financial Statements and Exhibits

(a) Financial Statements of Businesses Acquired
Not applicable

(b) Pro Forma Financial Information
Not applicable

(c) Exhibits

Edgar Filing: GENOMED INC - Form 8-K/A

(16.1) Letter from Rubin Brown pursuant to Item 304(a)(3) of Regulation S-B.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K/A to be signed on its behalf by the undersigned hereunto duly authorized.

GenoMed, Inc.

DATED: August 18, 2005

/s/ David Moskowitz

David Moskowitz

Chairman of the Board/Chief Executive Officer